Literature DB >> 20574543

Use of Antifungal Combination Therapy: Agents, Order, and Timing.

Melissa D Johnson1, John R Perfect.   

Abstract

Given the substantial morbidity and mortality related to invasive fungal infections, treatment with a combination of antifungal agents is often considered. A growing body of literature from in vitro studies, animal models, and clinical experience provides data evaluating this approach. This review describes combination antifungal strategies for the management of cryptococcal meningitis, invasive candidiasis, invasive aspergillosis, and rare mold infections. The potential effects that sequencing and timing have on the efficacy of such approaches are discussed, with a focus on recent clinical data in this arena.

Entities:  

Year:  2010        PMID: 20574543      PMCID: PMC2889487          DOI: 10.1007/s12281-010-0018-6

Source DB:  PubMed          Journal:  Curr Fungal Infect Rep        ISSN: 1936-3761


  62 in total

1.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.

Authors:  Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

2.  Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.

Authors:  A Thomas; V Korb; R Guillemain; T Caruba; V Boussaud; E Billaud; P Prognon; D Begué; B Sabatier
Journal:  J Clin Pharm Ther       Date:  2010-02       Impact factor: 2.512

Review 3.  Decision making in antifungal monotherapy versus combination therapy.

Authors:  Russell E Lewis
Journal:  Pharmacotherapy       Date:  2006-06       Impact factor: 4.705

4.  Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.

Authors:  Caitlin Reed; Ashraf Ibrahim; John E Edwards; Irwin Walot; Brad Spellberg
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

5.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

6.  Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis.

Authors:  D P Kontoyiannis; V Ratanatharathorn; J-A Young; J Raymond; M Laverdière; D W Denning; T F Patterson; D Facklam; L Kovanda; L Arnold; W Lau; D Buell; K A Marr
Journal:  Transpl Infect Dis       Date:  2008-10-08       Impact factor: 2.228

7.  Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B.

Authors:  O A Cornely; J Maertens; M Bresnik; A J Ullmann; R Ebrahimi; R Herbrecht
Journal:  J Antimicrob Chemother       Date:  2010-01       Impact factor: 5.790

8.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

Authors:  John H Rex; Peter G Pappas; Adolf W Karchmer; Jack Sobel; John E Edwards; Susan Hadley; Corstiaan Brass; Jose A Vazquez; Stanley W Chapman; Harold W Horowitz; Marcus Zervos; David McKinsey; Jeannette Lee; Timothy Babinchak; Robert W Bradsher; John D Cleary; David M Cohen; Larry Danziger; Mitchell Goldman; Jesse Goodman; Eileen Hilton; Newton E Hyslop; Daniel H Kett; Jon Lutz; Robert H Rubin; W Michael Scheld; Mindy Schuster; Bryan Simmons; David K Stein; Ronald G Washburn; Linda Mautner; Teng-Chiao Chu; Helene Panzer; Rebecca B Rosenstein; Jenia Booth
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

9.  Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America.

Authors:  Stanley W Chapman; William E Dismukes; Laurie A Proia; Robert W Bradsher; Peter G Pappas; Michael G Threlkeld; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

10.  Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient.

Authors:  J Y Z Li; T Y Yong; D I Grove; P T H Coates
Journal:  Transpl Infect Dis       Date:  2007-04-11       Impact factor: 2.228

View more
  24 in total

Review 1.  Unfolding antifungals: as a new foe to pancreatic ductal adenocarcinoma-a mini-review.

Authors:  Shruti Gupta; Atul Kumar; Kiran Kumar Tejavath
Journal:  Mol Biol Rep       Date:  2021-04-01       Impact factor: 2.316

2.  Current role of echinocandins in the management of invasive aspergillosis.

Authors:  Małgorzata Mikulska; Claudio Viscoli
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

Review 3.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

4.  Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.

Authors:  Alexander J Lepak; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

5.  Inhibition of Vesicular Transport Influences Fungal Susceptibility to Fluconazole.

Authors:  Liesbeth Demuyser; Katrien Van Dyck; Bea Timmermans; Patrick Van Dijck
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 6.  The challenge of managing fusariosis.

Authors:  Maged Muhammed; Jeffrey J Coleman; Herman A Carneiro; Eleftherios Mylonakis
Journal:  Virulence       Date:  2011-03-01       Impact factor: 5.882

7.  Lactoferrin-Derived Peptide Lactofungin Is Potently Synergistic with Amphotericin B.

Authors:  Kenya E Fernandes; Richard J Payne; Dee A Carter
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

8.  Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

9.  Amino acid substitutions at the major insertion loop of Candida albicans sterol 14alpha-demethylase are involved in fluconazole resistance.

Authors:  Nidia Alvarez-Rueda; Audrey Fleury; Florent Morio; Fabrice Pagniez; Louis Gastinel; Patrice Le Pape
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

10.  Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans.

Authors:  Ying-Lien Chen; Virginia N Lehman; Anna F Averette; John R Perfect; Joseph Heitman
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.